



UNIVERSITI PUTRA MALAYSIA

***SCREENING OF ARX, CDKL5 AND STXBP1 GENE MUTATIONS IN
MALAYSIAN PAEDIATRIC PATIENTS WITH EARLY-ONSET EPILEPTIC
ENCEPHALOPATHY BY HRM TECHNIQUE***

AMEERAH JAAFAR

FPSK(m) 22



**SCREENING OF *ARX*, *CDKL5* AND *STXBPI* GENE MUTATIONS IN
MALAYSIAN PAEDIATRIC PATIENTS WITH EARLY-ONSET EPILEPTIC
ENCEPHALOPATHY BY HRM TECHNIQUE**

By

AMEERAH JAAFAR

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of Master of Science**

June 2015

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

SCREENING OF *ARX*, *CDKL5* AND *STXBPI* GENE MUTATIONS IN MALAYSIAN PAEDIATRIC PATIENTS WITH EARLY-ONSET EPILEPTIC ENCEPHALOPATHY BY THE HRM TECHNIQUE

By

AMEERAH JAAFAR

June 2015

**Chair: Mohd Feizel Alsiddiq Mohd Fakharuddin, MD, MPAeds
Faculty: Medicine and Health Sciences**

Gene mutation is one of the etiologies of early-onset infantile Epileptic Encephalopathy (EE), an age-dependant seizure in infants which leads to brain defects. Previous studies have shown that several genes namely, Aristaless-related homeobox (*ARX*), Cyclin-dependent kinase-like 5 (*CDKL5*) and Syntaxin-binding protein 1 (*STXBPI*) are responsible for the pathophysiology of the syndrome. This study aims to investigate the clinical association of Malaysian subjects with known and novel mutation as well as developing an efficient and effective genetic screening method. In this study, 3 mL blood was extracted from the consented patients and control. The DNA was extracted (QiAamp blood mini kit, Qiagen), quantified on purity (ND-1000 spectrophotometer, NanoDrop Technologies, Inc.) and integrity (0.8% gel electrophoresis) and screened using High Resolution Melting Analysis (QiAamp Type-It HRM kit, Qiagen). Peripheral blood was obtained and genomic DNA was purified (DNA purification Kit, Intron Biotechnology). A total of 11 primer pairs were designed flanking 13 known mutations in all genes of interest. *ARX* exonic region was also screened for known and novel mutation. PCR specificity and efficiency were optimized using conventional PCR, Quantitative Polymerase Chain Reaction (qPCR) and High Resolution Melting Analysis (HRMA). Different melting profiles which distinguished homozygotes and heterozygotes based on the shape and temperature shifting were generated. Profiles were clustered and compared with homozygous wild type reference control. Samples from varying clusters were purified and subjected to direct DNA sequencing. All assays were successfully established. All known mutations reported previously were not found in Malaysian patients with 100% confirmation by sequencing results. A variant could be screened in duplicates of all samples within 3 hours. Subsequently, *ARX* exonic regions were also sequenced using published primers. No mutation was found in all patients samples. Nevertheless, HRMA is a robust, simple, rapid, accurate, efficient and cost-effective tool of screening for early onset infantile EE patients gene mutation.

Abstrak tesis yang di kemukakan kepada Senat Universiti Putra Malaysia Sebagai memenuhi keperluan untuk Ijazah Sarjana Sains

PENYARINGAN GEN MUTASI *ARX*, *CDKL5* AND *STXBPI* PADA PESAKIT PEDIATRIK 'EARLY-ONSET EPILEPTIC ENCEPHALOPATHY' DI MALAYSIA MENGGUNAKAN TEKNIK HRM

Oleh

AMEERAH JAAFAR

Jun 2015

**Pengerusi: Mohd Feizel Alsiddiq Mohd Fakhruddin, MD, MPAeds
Fakulti: Perubatan dan Sains Kesihatan**

Mutasi gen merupakan salah satu etiologi '*early-onset Epileptic Encephalopathy*' (EE), sejenis penyakit sawan mengikut peringkat umur bayi yang boleh membawa kepada kecacatan otak. Kajian telah menunjukkan bahawa beberapa gen iaitu '*Aristaless-related homeobox*' (*ARX*), '*Cyclin-dependent kinase-like 5*' (*CDKL5*) dan '*Syntaxin-binding protein 1*' (*STXBPI*) adalah berkait langsung dengan patofisiologi sindrom tersebut. Kajian ini dijalankan untuk mengkaji hubungan antara faktor klinikal pesakit EE di Malaysia dengan mutasi yang telah dikenalpasti serta yang baharu selain mencipta kaedah diidentifikasi genetik yang cekap dan berkesan. Dalam kajian ini, 3 mL darah telah diambil daripada pesakit dan subjek normal. DNA diekstrak (QiAamp blood mini kit, Qiagen), disaring bagi tujuan pengaslian (ND-100 0 spectrophotometer, NanoDrop Technologies, Inc.) dan integriti (0.8 % gel elektroforesis) dan diidentifikasi dengan menggunakan High Resolution Melting Analysis (QiAamp Type-It HRM kit, Qiagen). Darah peripheral diambil dan DNA genomic diidentifikasi (DNA purification Kit, Intron Biotechnology). 11 set primer telah dihasilkan merangkumi 13 mutasi dari gen-gen yang dikaji. Exon *ARX* juga dikaji untuk mutasi yang telah dikenalpasti dan juga yang baharu. PCR '*specificity*' dan '*efficiency*' telah dioptimumkan menggunakan kaedah konvensional PCR, '*Quantitative Polymerase Chain Reaction*' (qPCR) dan '*High Resolution Melting Analysis*' (HRMA). Profil yang pelbagai dapat membezakan homozygotes dan heterozigot berdasarkan bentuk dan suhu peralihan yang telah dijana. Kumpulan-kumpulan Profil telah dibandingkan dengan homozigot kawalan sebagai rujukan. Sampel dari kelompok yang berbeza-beza telah disaring dan dikenalpasti melalui kaedah '*DNA sequencing*'. Semua esei telah berjaya dioptimumkan. Mutasi-mutasi yang pernah dilaporkan sebelum ini tidak terdapat pada pesakit EE di Malaysia dibuktikan 100% oleh keputusan '*jujukan DNA*'. Varian A boleh diproses dalam semua sampel dalam masa 3 jam. Selain itu, exon *ARX* juga dikaji menggunakan primer yang telah dioptimumkan pada kajian yang lepas. Tiada mutasi didapati dalam semua sampel pesakit. Walaubagaimanapun, HRMA adalah alat identifikasi mutasi yang teguh, mudah, cepat, tepat, cekap dan kos efektif bagi mengesan mutasi gen pada pesakit EE.

ACKNOWLEDGEMENTS

My deepest gratitude to my supervisor, Dr. Mohd Feizel Alsiddiq Mohd Fakharuddin for his great ideas, advice and support. His valuable input and strong encouragement are the key determinants towards completing this project. Also, his financial support has given me the opportunity to test the hypothesis practically. My heartfelt thanks go to my co-supervisor, Dr. Ling King Hwa (Michael) who has exposed me to the real world of scientist with theoretical and practical assistance. His patience and advice are essential to ensure this project runs successfully. Not to forget his support and motivation that keeps me persistent in this research area.

To all group members of Neurobiology and Genetics group (NBGG) namely Mr. Siew Wei Hong, Ms. Tan Kai Leng, Ms. Angeline Leong, Mr. Usman Bala, Mr. Lee Han Chung, Mr. Shahidee Zainal Abidin, Ms. Lim Chai Ling, Ms. Melody Leong, Ms. Asween Rowena Sani and Mr. Hadri who energized my passion and stimulated my research interest, I am indebted for all the assistance be it physical, psychological or financial. Working together in a team was such a memorable experience I ever had. Special Thanks goes to Dr. Cheah Pike See who is leading, mentoring and educating us every now and then making us good researchers and individual specifically.

I would like to thank all paediatric neurologists who have been helping me in collecting patients' samples. Their simple and practical approaches made the work feasible and easy to conduct. Some names are worth to mention especially my supervisor, Dr. Feizel, Dr. Nor Azni Yahaya, Dr. Khoo Teik Beng, Dr. Heng Hock Sin and many more. My special thanks for Ms. Norfarazieda Hassan for helping me in control samples' blood collection regardless of her time, energy and money. Only Allah can reciprocate your help and kindness.

To the lecturers in Genetics and Regenerative Medicine Research Centre (GRMRC), Dr. Norshariza Nordin, Assoc. Professor Dr. Syahrilnizam Abdullah, Dr. Abhimanyu Veerakumarasivam, Dr. Chau De-Ming, Dr. Thilakavathy and Dr. Mok Pooi Ling thank you for the advice and support. I am honoured to be part of GRMRC which provides me such adequate resources and friendly environment. I would never forget the chance that has been given to me since my first day in Universiti Putra Malaysia. I believe the DNA of great heart in great laboratory was inherited from our pioneer, Professor Dr. Rozita Rosli who made this laboratory a great place to work. Thank you very much.

I would also like to thank Puan Salimah Mohd Said who has been helping me a lot with the research accounts, Puan Hazlen Saleh who takes care of our welfare and Puan Puspa Leela for our very important lab equipments. Many thanks also to Mr. Eric Goh (Qiagen) who has been ensuring my laboratory items were on bench continuously without a delay and Mr. Ng Chung Kiat (NHK Bioscience) who has been helping me a lot with the sequencing part. Special thanks to my seniors in technical assistance, Dr. Chan Soon Coy and Dr. Radha Kodiappan for valuable input and contribution.

To all my friends, Ms. Allisha Othman, Ms. Aimi Hanafi, Ms. Marlina Mahadzar, Ms. Nurussaadah Hamzah, Ms. Hamizah Saat, Ms. Rozita Mohd Sakri, Ms. Hoo Mun Fun, Ms. Carolindah Makena Nitmi, Mr. Suleiman Yusuf Alhaj, Mr. Akram Faisal and all members of GRMRC, thank you very much and wish you all the best, always.

Last but not least, my love, Mr. Aljojil Hamsah, my beloved mother, Mdm. Aminah Kamari, my sisters and brothers, Aisyah, Abidzar, Abdillah, and Ulfa, your endless love and support from the very beginning keep me moving and wanting to do more. I am thanking Allah for giving me such a great family which has been a great source of encouragement, inspiration and solace. Alhamdulillah. May Allah bless all of you.



This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Mohd Feizel Alsiddiq Mohd Fakharuddin, MD, MPAeds

Senior Lecturer
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Ling King Hwa (Michael), PhD

Senior Lecturer
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (research) Rules 2012;
- there is also no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____ Date: _____

Name and Matric No.: _____

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____
Name of
Chairman of
Supervisory
Committee: _____

Signature: _____
Name of
Member of
Supervisory
Committee: _____



TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	ii
ACKNOWLEDGEMENTS	iii
APPROVAL	iv
DECLARATION	vii
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF APPENDICES	xiii
LIST OF ABBREVIATIONS	xiv
CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	3
2.1 Early onset infantile epileptic encephalopathy	3
2.1.1 Overview	3
2.1.2 Spectrum of etiologies	3
2.1.3 Characteristics, stages and progression	3
2.2 Frequently associated genes	4
2.2.1 Aristaless-related homeobox (<i>ARX</i>)	4
2.2.2 Cyclin-dependent Kinase-like-5 (<i>CDKL5</i>)	5
2.2.3 Syntaxin-binding protein-1 (<i>STXBPI</i>)	5
2.3 Role of <i>ARX</i> , <i>CDKL5</i> , and <i>STXBPI</i> genes in early infantile EE	6
2.3.1 Known causative mutations	6
2.3.2 Type and site of mutation implicated the severity of onset	11
2.3.3 Genetic susceptibility on different gender	11
2.4 Mutation screening methods	11
2.4.1 High-resolution melting	11
3 METHODOLOGY	
3.1 Summary of overall methodology	16
3.2 Phase I: Subject selection	13
3.2.1 Study design	13
3.2.2 Study location	13
3.2.3 Sample size determination	13
3.2.4 Subject sampling method	13
3.2.5 Ethics	15
3.2.6 Data collection	15
3.2.7 Blood collection	15
3.3 Phase II: Genomic DNA Extraction	17
3.3.1 Buffy coat separation	17
3.3.2 DNA extraction using QIAamp DNA blood mini kit	17

3.3.3	DNA quantification	18
3.3.3.1	Determination of concentration and purity	18
3.3.3.2	Determination of molecular weight and integrity	18
3.4	Phase III: Amplification of starting material	18
3.4.1	Assay design	18
3.4.2	Primer design	19
3.4.2.1	Preparation of stock and working primer solution	20
3.4.3	PCR Optimization	20
3.4.3.1	Gradient PCR	20
3.4.3.2	Agarose Gel Electrophoresis	20
3.4.3.3	Real-time PCR	22
3.5	Phase IV: Mutation screening of causative mutation	22
3.5.1	High-resolution melting assay	22
3.5.1.1	HRM analysis	22
3.5.2	<i>ARX</i> exon screening	23
3.5.2.1	Conventional PCR	23
3.5.2.2	Gel Electrophoresis	23
3.6	Phase V: DNA sequencing	25
3.6.1	DNA purification	25
3.6.2	Dye terminator cycle sequencing	25
4	RESULTS AND DISCUSSION	26
4.1	Patients demographic data	26
4.2	Development of screening methods	29
4.2.1	Selected SNP	29
4.2.2	Gradient Polymerase Chain Reaction (PCR)	29
4.2.3	Real-time PCR	35
4.2.4	Dye terminator cycle sequencing	40
4.3	Screening of mutation	52
4.3.1	DNA extraction	52
4.3.2	Pathogenic mutation screening in <i>ARX</i> , <i>CDKL5</i> and <i>STXBPI</i>	53
4.3.2.1	<i>ARX</i> selected causative SNP mutation	53
4.3.2.2	<i>CDKL5</i> selected causative SNP mutation	53
4.3.2.3	<i>STXBPI</i> selected causative SNP mutation	55
4.3.3	Screening of novel mutation in <i>ARX</i> exons using PCR	56
5	CONCLUSION	57
	REFERENCES	58
	APPENDICES	64
	BIODATA OF STUDENT	70

LIST OF TABLES

Table		Page
2.1	Known SNPs' exons, mutation involved, type of mutation, protein change and allele status on dbSNP	9
3.1	Summary of selected SNPs in <i>ARX</i> , <i>CDKL5</i> and <i>STXBP1</i>	19
3.2	Primer sequences of <i>ARX</i> , <i>CDKL5</i> and <i>STXBP1</i> known mutation	21
3.3	Primer sequences of <i>ARX</i> exons	24
4.1	Annealing temperature of the <i>ARX</i> , <i>CDKL5</i> and <i>STXBP1</i> designed primers flanking thirteen mutations.	30
4.2	Optimised PCR Profiles for amplification of SNP in <i>ARX</i> , <i>CDKL5</i> and <i>STXBP1</i> genes	31
4.3	SNP classes defined by Venter <i>et al.</i> (2001)	36

LIST OF FIGURES

Figure		Page
2.1	Chromosomal loci of genes associated with early onset infantile epileptic encephalopathy	8
2.2	Schematic representation of gene structure and SNP localization of (a) <i>ARX</i> (b) <i>CDKL5</i> (c) <i>STXBPI</i> .	10
3.1	Flow of subjects recruitment following inclusion/exclusion criteria.	15
4.1	Pie chart of patients age group	27
4.2	Pie chart of patients gender	28
4.3	Classification of patients according to different (a) seizure type (b) syndrome (c) EEG type	28
4.4	Gradient PCR gel electrophoresis of <i>ARX</i> c.81C>G PCR product	32
4.5	PCR gel electrophoresis of <i>CDKL5</i> c.175C>T PCR product	32
4.6a	Gradient PCR gel electrophoresis of <i>STXBPI</i> c.1631G>A	33
4.6b	Gradient PCR gel electrophoresis of <i>STXBPI</i> c.328T>G	33
4.6c	Gradient PCR gel electrophoresis of <i>STXBPI</i> c.1162C>T	34
4.7	Touchdown PCR of <i>ARX</i> exons	34
4.8	Derivative meting curve and normalize curve of <i>ARX</i> c.81C>G	37
4.9	Derivative meting curve and normalize curve of <i>CDKL5</i> c.175C>T	38
4.10	Derivative meting curve and normalize curve of <i>STXBPI</i> c.1631G>A	39
4.11	Sequence alignment of <i>CDKL5</i> targeted region	41
4.12	Screening of <i>ARX</i> c.81C>G	42
4.13	Screening of <i>STXBPI</i> c.1631G>A	43
4.14	Screening of <i>STXBPI</i> c.539G>A	44
4.15	Screening of <i>STXBPI</i> c.328T>G	45
4.16	Screening of <i>STXBPI</i> c.251T>A	46
4.17	Screening of <i>STXBPI</i> c.1162C>T	47
4.18	Screening of <i>CDKL5</i> c.175C>T, c.183delT, c.215T>A	48
4.19	Screening of <i>CDKL5</i> c.455G>T	49
4.20	Screening of <i>CDKL5</i> c.525A>T, c.539C>T	50
4.21	Screening of <i>CDKL5</i> c.838_847del10	51
4.22	Agarose gel electrophoresis of patient's genomic DNA post-extraction	52

LIST OF APPENDICES

Appendix		Page
A	Patient information sheet and consent form	64
B	Genetic test request form	68
C	DNA purity of subjects' samples	69



LIST OF ABBREVIATIONS

1X	One time
6X	Six times
AD	Autosomal dominant
ARX	Aristaless-related homeobox
bp	Base pair
<i>CDKL5</i>	Cyclin-dependent Kinase-Like 5
CI	Confidence interval
dbSNP	Single Nucleotide Polymorphism Database
DNA	Deoxyribonucleic acid
dNTPs	Deoxynucleotidephosphates
EDTA	Ethylenediaminetetraacetic acid
EE	Epileptic encephalopathy
HRMA	High Resolution Melting Analysis
LOVD	Leiden Open Variants Database
m	Miligram
M	Molar
MOH	Ministry of Health
MREC	Medical Research Ethics Committee
NaCl	Sodium chloride
NaOH	Sodium hydroxide
NCBI	National Centre of Biotechnology Information
ng	Nanogram
OMIM	Online Mendelian Inheritance in Man
PBS	Phosphate Buffered Saline
PCR	Polymerase Chain Reaction
RPM	Revolutions per minute
rs	Reference SNP number
SNP	Single Nucleotide Polymorphism
<i>STXBP1</i>	Syntaxin binding protein 1
Ta	Annealing temperature
TAE	Tris-acetate-EDTA
Tm	Melting temperature
UPM	Universiti Putra Malaysia
UTR	Untranslated region
UV	Ultraviolet
V	Volt
w/v	Weight/ volume
XLD	X-linked dominant
XLR	X-linked recessive
µL	Microlitre

Gene mutation is one of the etiologies of early-onset infantile Epileptic Encephalopathy (EE), an age-dependant seizure in infants which leads to brain defects. Previous studies have shown that several genes namely, Aristaless-related homeobox (*ARX*), Cyclin-dependent kinase-like 5 (*CDKL5*) and Syntaxin-binding protein 1 (*STXBPI*) are responsible for the pathophysiology of the syndrome. This study aims to investigate the clinical association of Malaysian subjects with known and novel mutation as well as developing an efficient and effective genetic screening method. In this study, 3 mL blood was extracted from the consented patients and control. The DNA was extracted (QiAamp blood mini kit, Qiagen), quantified on purity (ND-1000 spectrophotometer, NanoDrop Technologies, Inc.) and integrity (0.8% gel electrophoresis) and screened using High Resolution Melting Analysis (QiAamp Type-It HRM kit, Qiagen). Peripheral blood was obtained and genomic DNA was purified (DNA purification Kit, Intron Biotechnology). A total of 11 primer pairs were designed flanking 13 known mutations in all genes of interest. *ARX* exonic region was also screened for known and novel mutation. PCR specificity and efficiency were optimized using conventional PCR, Quantitative Polymerase Chain Reaction (qPCR) and High Resolution Melting Analysis (HRMA). Different melting profiles which distinguished homozygotes and heterozygotes based on the shape and temperature shifting were generated. Profiles were clustered and compared with homozygous wild type reference control. Samples from varying clusters were purified and subjected to direct DNA sequencing. All assays were successfully established. All known mutations reported previously were not found in Malaysian patients with 100% confirmation by sequencing results. A variant could be screened in duplicates of all samples within 3 hours. Subsequently, *ARX* exonic regions were also sequenced using published primers. No mutation was found in all patients samples. Nevertheless, HRMA is a robust, simple, rapid, accurate, efficient and cost-effective tool of screening for early onset infantile EE patients gene mutation.

CHAPTER 1

INTRODUCTION

Early onset infantile epileptic encephalopathy (EE) is a subgroup of infantile epilepsy affecting infants at the age of onset typically less than a year of life. The seizures are very frequent and severe leading to progressive loss of cerebral function (Noh *et al.*, 2012). The diagnosis of early onset infantile EE involves clinical examination and electroencephalogram (EEG) to determine the presence of the syndrome. Apart from electro-clinical data, molecular investigation has also been used recently. With the advancement of molecular tools, genetic abnormalities become a key determinant of idiopathic early onset EE, a type of infantile epilepsy arising from unknown causes (Tavyev *et al.*, 2012). Other than idiopathic, there is also symptomatic early onset infantile EE such as hypoxic ischemic encephalopathy, infection, metabolic abnormalities and brain structural defects (Alam *et al.*, 2012).

To improve the condition of Malaysian early onset infantile EE patients from genetic aspect, screening of known causative mutation is practically helpful and providing new insights to other novel approaches. In this study, three genes of interest namely Aristaless-related homeobox (*ARX*), Cyclin-dependent kinase-like 5 (*CDKL5*) and Syntaxin binding protein 1 (*STXBPI*) genes were selected among other genes which are frequently associated with early onset infantile EE patients. *ARX* and *CDKL5* are well-known X-linked genes beneficial for further familial studies while *STXBPI* are being widely investigated as a new gene on chromosome 9 increasingly affecting epileptic patients worldwide (Saitu *et al.*, 2008). The association of early onset infantile EE with an underlying genetic background has drawn a great concern among health practitioners. Multiple genes were unveiled from genomic level up to the protein and biological function related to patient's clinical phenotype. Despite the increasing information on genetic impairment, low sample size for population-based study would still require the significant global involvement. Nevertheless, studies from different population will be an added value to the existing data.

It has been reported that specific causative mutation at specific site may produce a degree of severity thus assisting the health practitioner to make a correct diagnosis and come out with a proper treatment at different epileptic stage. The identification of the causative mutation may serve as a predictive or a diagnostic testing that increases the understanding of varying aetiologies, omits the unnecessary assessment, and reduces the need of invasive investigations. It may also decrease the expensive cost, provide early prediction of the outcome that assists the prescription of anti-epileptic drugs and enables effective patients counselling (Alliance, 2010). Furthermore, on the other side, it may ease the psychological burden of the relatives that may have attributed other non-evidence based as causes thus lead to poor management of their child. The presence of causative mutation indicates that the patients has positive early onset EE which gives a confirmation to the family members. Necessary precautions can also be taken while dealing with patients' serious conditions.

To delineate the role and mechanism of the causative mutation, in particular, single nucleotide polymorphism (SNPs), the genetic background of early onset infantile EE

patients has to be characterized. A small scale study is essential to test the effect size that determines the importance of large population-based study in the future. Using a small sample size of Malaysian idiopathic early onset infantile EE patients, the hypothesis on the presence of the known mutations among patients' samples shall be a great benefit in epilepsy research in Malaysia. The objective is to screen known causative mutations that have been reported previously in Malaysian early onset infantile EE patients using High Resolution Melting Analysis (HRMA) as well as assessing clinical manifestation of the patients.

Meanwhile, the development of screening method facilitates the detection of gene mutation worldwide. However, the current methods such as direct sequencing, Restriction Fragment Length Polymorphism (RFLP), single strand chain polymorphism (SSCP) to screen the genes are considered laborious, expensive and impractical for a routine test. High resolution melting analysis (HRMA) is rapid to effectively and efficiently discriminate patient genetic profiles. Based on the temperature, differences in amino acid sequence can be distinguished accurately (Reed *et al.*, 2007). Although sequencing is a gold standard in mutation detection, due to its simplicity and reasonable cost, HRMA is more practical as a routine diagnostic method in lab-based setting making the daily patient diagnosis possible in a small clinical setting.

In general, this study focuses in identifying the presence of known causative mutation reported previously in Malaysian early onset infantile EE patients while finding the novel mutation in one of the gene of interest, *ARX*. The genetic information was compared with clinical data to derive as possible association. A rapid genetic screening method using a simple approach was also developed to serve as a routine screening diagnostic tool in a clinical setting in the future.

The main objective is to investigate the association of the *ARX*, *CDKL5* and *STXBPI* gene mutation in paediatric patients with early onset infantile epileptic encephalopathy. In specific, this study aims:

1. To screen *ARX*, *CDKL5* and *STXBPI* known gene mutations in Malaysian early onset infantile EE patients.
2. To investigate the frequency of *ARX*, *CDKL5* and *STXBPI* gene mutations among Malaysian early onset infantile EE patients.
3. To assess the full clinical feature of patients with early onset infantile EE associated with *ARX*, *CDKL5* and *STXBPI* gene mutations.

It is expected that the current study will give a better understanding on the effect of pathogenic mutations in *ARX*, *CDKL5* and *STXBPI* genes towards Malaysian early onset infantile EE patients as well as establishing a simple, rapid and efficient genetic screening method. It is also hoped that the study may assist the patient's diagnosis more effectively and efficiently.

REFERENCES

- Alam, S., & Lux, A. L. (2012). Epilepsies in infancy. *Archives of Disease in Childhood*, 97(11), 985-92.
- Alliance, G., & District of Columbia Department of Health. (2010). Diagnosis of a Genetic Disease.
- Archer, H. L., Evans, J., Edwards, S., Colley, J., Newbury-Ecob, R., O'Callaghan, F., Huyton, M., et al. (2006). CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. *Journal of Medical Genetics*, 43(9), 729-734.
- Artuso, R., Mencarelli, M. A., Polli, R., Sartori, S., Ariani, F., Pollazzon, M., Marozza, A., et al. (2010). Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria. *Brain and Development*, 32(1), 17-24.
- Bahi-Buisson, N., Nectoux, J., Rosas-Vargas, H., Milh, M., Boddaert, N., Girard, B., Cances, C., et al. (2008). Key clinical features to identify girls with CDKL5 mutations. *Brain : a Journal of Neurology*, 131(10), 2647-2661.
- Bahi-Buisson, N., Villeneuve, N., Caietta, E., Jacquette, A., Maurey, H., Matthijs, G., Van Esch, H., et al. (2012). Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. *American Journal of Medical genetics. Part A*, 158(7), 1612-9.
- Berg, A. T., Berkovic, S. F., Brodie, M. J., Buchhalter, J., Cross, J. H., Emde Boas, W. van, Engel, J., et al. (2010). Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia*, 51(4), 676-685.
- Bettella, E., Di Rosa, G., Polli, R., Leonardi, E., Tortorella, G., Sartori, S., & Murgia, a. (2013). Early-onset epileptic encephalopathy in a girl carrying a truncating mutation of the ARX gene: rethinking the ARX phenotype in females. *Clinical Genetics*, 84(1), 82-5.
- Bienvenu, T., Poirier, K., Friocourt, G., Bahi-Buisson, N., Beaumont, D., Fauchereau, F. et al. (2002). ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. *Human Molecular Genetics*, 11, 981-991.
- Castrén, M., Gaily, E., Tengström, C., Lähdetie, J., Archer, H., & Ala-Mello, S. (2011). Epilepsy caused by CDKL5 mutations. *European Journal of Paediatric Neurology*, 15(1), 65-69.
- Chen, Q., Zhu, Y.-C., Yu, J., Miao, S., Zheng, J., Xu, L., Zhou, Y., et al. (2010). CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 30(38), 12777-12786.
- Daye, Z. J., Li, H., & Wei, Z. (2012). A powerful test for multiple rare variants association studies that incorporates sequencing qualities. *Nucleic Acids Research*, 40(8):60.
- Demos, M. K., Fullston, T., Partington, M. W., Gécz, J., Gibson, W. T. (2009). Clinical study of two brothers with a novel 33 bp duplication in the ARX gene. *American Journal of Medical Genetics*, 149, 1482 – 1486.
- Depienne, C, Gourfinkel-An, I, Baulac, S, LeGuern, E (2010). Genes in infantile epileptic encephalopathies. *Epilepsia*, 51, 69.
- Deprez, L., Jansen, A., & De Jonghe, P. (2009). Genetics of epilepsy syndromes starting in the first year of life. *Neurology*, 72(3), 273-281.

- Djukic, A., Lado F. A., Shinnar S, Moshe SL (2006). Are early myoclonic encephalopathy (EME) and the Ohtahara syndrome (EIEE) independent of each other? *Epilepsy Research*, 70(1), S68–S76.
- Dulac, O. (2001). Epileptic Encephalopathies. *Epilepsia*, 42(3), 23-26.
- Ekşioğlu, Y. Z., Pong, A. W., & Takeoka, M. (2011). A novel mutation in the aristaless domain of the ARX gene leads to Ohtahara syndrome, global developmental delay, and ambiguous genitalia in males and neuropsychiatric disorders in females. *Epilepsia*.
- Elia, M., Falco, M., Ferri, R. et al. (2008). CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. *Neurology*, 71, 997–999.
- Erali, M. & Wittwer, C. T. (2008). High resolution melting analysis for gene scanning. *Methods San Diego Calif*, 50(4), 250-261.
- Erez, A., Patel, A. J., Wang, X., Xia, Z., Bhatt, S. S., Craigen, W., et al. (2009) Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder. *Neurogenetics*.
- Feero, W. G., & Guttmacher, A. E. (2014). Genomics, personalized medicine, and pediatrics. *Academic Pediatrics*.
- Fichou, Y., Bieth, E., Bahi-Buisson, N., et al. (2009). Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. *Neurology*, 73, 77-8.
- Fullston, T., Brueton, L., Willis, T., Philip, S., MacPherson, L., Finniss, M., Gecz, J., et al. (2010). Ohtahara syndrome in a family with an ARX protein truncation mutation (c.81C>G/p.Y27X). *European Journal of Human Genetics : EJHG*, 18(2), 157-162.
- Giordano, L., Sartori, S., Russo, S., Accorsi, P., Galli, J., Tiberti, A., Bettella, E., et al. (2010). Familial Ohtahara syndrome due to a novel ARX gene mutation. *American Journal of Medical Genetics. Part A*.
- Gorlov, I. P., Gorlova, O. Y., Sunyaev, S. R., Spitz, M. R., & Amos, C. I. (2008). Shifting Paradigm of Association Studies: Value of Rare Single-Nucleotide Polymorphisms. *American Journal of Human Genetics*, 82(1), 100-112.
- Gronskov, K., Hjalgrim, H., Nielsen, I. M., Brondum-Nielsen, K. (2004). Screening of the ARX gene in 682 retarded males. *European Journal of Human Genetics*, 12, 701– 705.
- Guerra, R., Yu., Z. (2008). Single Nucleotide Polymorphism And Their Applications. [Computational and Statistical Approaches to Genomics](#). pp 311-349.
- Guerrini, R., Moro, F., Kato, M., Barkovich, A. J., Shiihara, T., McShane, M. A., Hurst, J., et al. (2007). Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. *Neurology*.
- Guthery, S. L., Salisbury, B. A., Pungliya, M. S., Stephens, J. C., & Bamshad, M. (2007). The structure of common genetic variation in United States populations. *American Journal of Human Genetics*, 81(6), 1221-1231.
- Heron, S. E., Ong, Y. S., Yendle, S. C., McMahon, J. M., Berkovic, S. F., Scheffer, I. E., & Dibbens, L. M. (2013). Mutations in PRRT2 are not a common cause of infantile epileptic encephalopathies. *Epilepsia*, 54(5), 86-9.
- Intusoma, U., Hayeeduereh, F., Plong-On, O., Sripo, T., Vasikananonte, P., Janjindamai, S., Lusawat, A., et al. (2011). Mutation screening of the CDKL5 gene in cryptogenic infantile intractable epilepsy and review of clinical sensitivity. *European Journal of Paediatric Neurology*, 15(5), 432-438.
- Kalscheuer, V. M., Tao, J., Donnelly, A., Hollway, G., Schwinger, E., Kübart, S., Menzel, C., et al. (2003). Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. *American Journal of Human Genetics*.

- Kato, M. (2006). A new paradigm for West syndrome based on molecular and cell biology. *Epilepsy Research*, 70(1), S87-95.
- Kato, M., Saitoh, S., Kamei, A., Shiraiishi, H., Ueda, Y., Akasaka, M., Tohyama, J., et al. (2007). A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). *American Journal of Human Genetics*.
- Kato, M., Yamagata, T., Kubota, M., Arai, H., Yamashita, S., Nakagawa, T., Fujii, T., et al. (2013). Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. *Epilepsia*, 54(7), 1282-7.
- Kitamura, K., Yanazawa, M., Sugiyama, N., Miura, H., Iizuka-Kogo, A., Kusaka, M., et al. (2002). Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. *Nature Genetics*, 32, 359-369.
- Korff, C. M., & Nordli, D. R. (2006). Epilepsy Syndromes in Infancy. *Pediatric Neurology*, 34(4), 253-263.
- Kraja, A. T., Czajkowski, J., Feitosa, M. F., Borecki, I. B., & Province, M. A. (2011). Detecting disease rare alleles using single SNPs in families and haplotyping in unrelated subjects from the Genetic Analysis Workshop 17 data. *BMC Proceedings*.
- Kwok, P. Y., Chen, X. (2003). Detection of single nucleotide polymorphisms. *Current Issues in Molecular Biology*, 5, 43-60.
- Laperuta, C., Spizzichino, L., D'Adamo, P., Monfregola, J., Maiorino, A., D'Eustacchio, A., et al. (2007). MRX87 family with Aristaless X dup24bp mutation and implication for polyAlanine expansions. *BMC Medical Genetics*, 8, 25.
- Le, S. Q. & Durbin, R. (2011). SNP detection and genotyping from low-coverage sequencing data on multiple diploid samples. *Genome Research*, 21, 952-960.
- Li, R. Q. et al. (2009). SNP detection for massively parallel whole-genome resequencing. *Genome Research*, 19, 1124-1132.
- Liang, J.-S., Shimojima, K., Takayama, R., Natsume, J., Shichiji, M., Hirasawa, K., Imai, Kaoru, et al. (2011). CDKL5 alterations lead to early epileptic encephalopathy in both genders. *Epilepsia*, 52(10), 1835-42.
- Liew, M., Pryor, R., Palais, R., Meadows, C., Erali, M., Lyon, E., & Wittwer, C. (2004). Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. *Clinical Chemistry*, 50(7), 1156-1164.
- McKenzie, O., Ponte, I., Mangelsdorf, M., Finnis, M., Colasante, G., Shoubbridge, C., Stifani, S., et al. (2007). Aristaless-related homeobox gene, the gene responsible for West syndrome and related disorders, is a Groucho/transducin-like enhancer of split dependent transcriptional repressor. *Neuroscience*, 146(1), 236-247.
- Mei, D., Marini, C., Novara, F., Bernardina, B. D., Granata, T., Fontana, E., Parrini, E., et al. (2010). Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy. *Epilepsia*, 51(4), 647-654.
- Melani, F., Mei, D., Pisano, T., Savasta, S., Franzoni, E., Ferrari, A. R., Marini, C., et al. (2011). CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life. *Developmental Medicine and Child Neurology*, 53(4), 354-360.
- Mignot, C., Moutard, M. L., Trouillard, O., et al. (2011). STXBP1-related encephalopathy presenting as infantile spasms and generalized tremor in three patients. *Epilepsia*, 52, 1820-7.
- Mirzaa, G. M., Paciorkowski, A. R., Marsh, E. D., Berry-Kravis, E. M., Medne, L., Grix, A., Wirrell, E. C., et al. (2013). CDKL5 and ARX mutations in males with early-onset epilepsy. *Pediatric Neurology*, 48(5), 367-377. Nawara, M., Szczaluba, K.,

- Chrzanowska, K., Pilch, J., Bal, J., et al. (2006). The ARX mutations: a frequent cause of X-linked mental retardation. *American Journal of Medical Genetics*, 140, 727–32.
- Nectoux, J., Heron, D., Tallot, M., Chelly, J., Bienvenu, T. (2006) Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome. *Clinical Genetics*, 70, 29–33.
- Nemos, C., Lambert, L., Giuliano, F., Doray, B., Roubertie, A., Goldenberg, A., Delobel, B., et al. (2009). Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature. *Clinical Genetics*, 76(4), 357-371.
- Noh, G. J., Jane Tavyev Asher, Y., & Graham, J. M. (2012). Clinical review of genetic epileptic encephalopathies. *European Journal of Medical Genetics*, 55(5), 281-298.
- Ohtahara, S., Ishida, T., Oka, E. (1976). On the specific age-dependent epileptic syndrome. The early infantile epileptic encephalopathy with burst-suppression, *No to Hattatsu (Tokyo)*, 8, 270-280.
- Ohtahara, S., Yamatogi, Y. (2006). Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy, *Epilepsy Research*, 70(1), S58-S67.
- Palais, R. A., Liew, M. A., & Wittwer, C. T. (2005). Quantitative heteroduplex analysis for single nucleotide polymorphism genotyping. *Analytical Biochemistry*, 346(1), 167-175.
- Panayiotopoulos, C. P. (2005), Idiopathic Generalized Epilepsies: A Review and Modern Approach. *Epilepsia*,
- Partington, M. W., Turner, G., Boyle, J., Gecz, J. (2004). Three new families with X-linked mental retardation caused by the 428–451dup (24 bp) mutation in ARX. *Clinical Genetics*, 66, 39–45.
- Pintaudi, M., Baglietto, M. G., Gaggero, R., Parodi, E., Pessagno, A., Marchi, M., Russo, S., et al. (2008). Clinical and electroencephalographic features in patients with CDKL5 mutations: Two new Italian cases and review of the literature. *Epilepsy and Behavior*, 12(2), 326-331.
- Poirier, K., Van Esch, H., Friocourt, G., Saillour, Y., Bahi, N., Backer, S., Souil, E., et al. (2004). Neuroanatomical distribution of ARX in brain and its localisation in GABAergic neurons. *Molecular Brain Research*, 122(1), 35-46.
- Rademacher, N., Hambrock, M., Fischer, U., Moser, B., Ceulemans, B., Lieb, W., et al. (2011). Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features (Letter). *Neurogenetics*, 12, 165-167.
- Raymond, L., Diebold, B., Leroux, C., Maurey, H., Drouin-Garraud, V., Delahaye, A., Dulac, O., et al. (2013). Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: Identification of novel mutations. *Gene*, 512(1), 70-75.
- Reed, G. H., Kent, J. O., Wittwer, C. T. (2007). High-resolution DNA melting analysis for simple and efficient molecular diagnostics. *Pharmacogenomics*, 8(6), p. 597-608.
- Reish, O., Fullston, T., Regev, M., Heyman, E., & Gecz, J. (2009). A novel de novo 27 bp duplication of the ARX gene, resulting from postzygotic mosaicism and leading to three severely affected males in two generations. *American Journal of Medical Genetics. Part A*.
- Ricciardi, S., Kilstrup-Nielsen, C., Bienvenu, T., Jacquette, A., Landsberger, N., Broccoli, V. (2009) CDKL5 influences RNA splicing activity by its association

- to the nuclear speckle molecular machinery. *Human Molecular Genetics*, 18, 4590–4602.
- Rosas-Vargas, H., Bahi-Buisson, N., Philippe, C., Nectoux, J., Girard, B., N’Guyen-Morel, M. A., et al. (2008). Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy. *Journal of Medical Genetics*, 45, 172–8.
- Russo, S., Marchi, M., Cogliati, F., Bonati, M. T., Pintaudi, M., Veneselli, E., Saletti, V., et al. (2009). Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes. *Neurogenetics*, 10(3), 241-250.
- Russo, S., Marchi, M., Cogliati, F., Bonati, M. T., Pintaudi, M., Veneselli, E., Saletti, V., et al. (2009). Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes. *Neurogenetics*, 10(3), 241-250.
- Saitsu, H., Kato, M., Mizuguchi, T., Hamada, K., Osaka, H., Tohyama, J., Uruno, K., et al. (2008). De novo mutations in the gene encoding *STXBP1* (*MUNC18-1*) cause early infantile epileptic encephalopathy. *Nature Genetics*, 40(6), 782-8.
- Saitsu, H., Kato, M., Okada, I., Orii, K. E., Higuchi, T., Hoshino, H., Kubota, M., et al. (2010). *STXBP1* mutations in early infantile epileptic encephalopathy with suppression-burst pattern. *Epilepsia*, 51(12), 2397-2405.
- Saletti, V., Canafoglia, L., Cambiaso, P., Russo, S., Marchi, M., & Riva, D. (2009). A CDKL5 mutated child with precocious puberty. *American Journal of Medical Genetics. Part A*.
- Sampaio, M., Rocha, R., Biskup, S., & Leão, M. (2013). Novel *STXBP1* Mutations in 2 Patients with Early Infantile Epileptic Encephalopathy. *Journal of Child Neurology*, 1-4.
- Scala, E., Ariani, F., Mari, F., et al. (2005). CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. *Journal of Medical Genetics*, 42, 103-7.
- Stalpers, Xenia, L., Spruijt, Liesbeth, Yntema, Helger, G., Verrips, A. (2012). Clinical Phenotype of 5 Females With a CDKL5 Mutation. *Journal of Child Neurology*, 27, 90.
- Strømme, P., Mangelsdorf, M. E., Shaw, M. A., Lower, K. M., Lewis, S. M. E., Bruyere, H., Lütcherath, V., et al. (2002). Mutations in the human ortholog of *Aristaless* cause X-linked mental retardation and epilepsy. *Nature Genetics*, 30(4), 441-445.
- Strømme, P., Mangelsdorf, M. E., Shaw, M. A., Lower, K. M., Lewis, S. M. E., Bruyere, H., Lütcherath, V., et al. (2002). Mutations in the human ortholog of *Aristaless* cause X-linked mental retardation and epilepsy. *Nature Genetics*, 30(4), 441-445.
- Suri, M. (2005). The phenotypic spectrum of ARX mutations. *Development of Medical Child Neurology*.47, 133 – 137.
- Tan, May, H., Gécz, J., Shoubridge, C. (2013). PCR Amplification and Sequence Analysis of GC-Rich Sequences: *Aristaless* -Related Homeobox Example : [Tandem Repeats in Genes, Proteins, and Disease](#), *Methods and Protocols. Methods in Molecular Biology*, 1017, pp 105-120.
- Tao, J., Van Esch, H., Hagedorn-Greiwe, H., Hoffmann, K., Moser, B., Raynaud, M., et al., (2004). Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation, *American Journal of Medical Genetics*. 75, 1149-1154.
- Tavyev Asher, Y. J., & Scaglia, F. (2012). Molecular bases and clinical spectrum of early infantile epileptic encephalopathies. *European Journal of Medical Genetics*, 55(5), 299-306.
- Thambyayah, M. (2001). Early epileptic encephalopathies including West syndrome: A 3-year retrospective study from Klang Hospital, Malaysia. *Brain and Development*, 23, pp. 603-604.

- Toldo, I., Bruson, A., Casarin, A., Salviati, L., Boniver, C., Sartori, S., Montagna, P., et al. (2011). Polymorphisms of the SCN1A gene in children and adolescents with primary headache and idiopathic or cryptogenic epilepsy: is there a linkage? *The Journal of Headache and Pain*, 12(4), 435-441.
- Uyanik, G., Aigner, L., Martin, P., Gross, C., Neumann, D., Marschner-Schafer, H., et al. (2003) ARX mutations in X-linked lissencephaly with abnormal genitalia. *Neurology*, 61, 232-235.
- Van Esch, H., Jansen, A., Bauters, M. et al. (2007). Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes. *American Journal of Medical Genetics*, 143, 364–369.
- Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., et al. (2001) The sequence of the human genome. *Science*; 291, 1304–51.
- Wallerstein, R., Sugalski, R., Cohn, L., Jawetz, R., & Friez, M. (2008). Expansion of the ARX spectrum. *Clinical Neurology and Neurosurgery*, 110(6), 631-634.
- Weaving, L. S., Christodoulou, J., Williamson, S. L., Friend, K. L., McKenzie, O. L. D., Archer, H., Evans, J., et al. (2004). Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. *American Journal of Human Genetics*, 75(6), 1079-1093.
- Weaving, L., Ellaway, C., Gecz, J., & Christodoulou, J. (2005). Rett syndrome: clinical review and genetic update. *Journal of Medical Genetics*, 42(1), 1-7.
- Zhou, L., Wang, L., Palais, R., Pryor, R., & Wittwer, C. T. (2005). High-resolution DNA melting analysis for simultaneous mutation scanning and genotyping in solution. *Clinical Chemistry*, 51(10), 1770-1777